Skip to main content

and
  1. Article

    Open Access

    RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer

    RAS mutant (MT) metastatic colorectal cancer (mCRC) is resistant to MEK1/2 inhibition and remains a difficult-to-treat group. Therefore, there is an unmet need for novel treatment options for RASMT mCRC. RALA and...

    Hajrah Khawaja, Andrew Campbell, Jamie Z. Roberts, Arman Javadi in Cell Death & Disease (2020)